Portola reports Phase III antidote data

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) rose $2.68 to $40.76 on Monday after reporting full data from the

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE